Aktie im Fokus: COURSE ALERT: Vidac Pharma with strong new cooperation in Germany!

Dear readers,

Hardly any other industry has grown as strongly in recent years as the pharmaceutical industry. The achievements of modern biotechnology, the application of results from genome research as well as the increasing knowledge of how many diseases develop have led to an enormous surge in innovation in the development of new drugs. For pharmaceutical companies and thus for pharmaceutical shares, this development continues to mean bright prospects.

This is exemplified by Vidac Pharma, the highly innovative isralic pharmaceutical company that has set its sights on nothing less than beating cancer. Since our initial review and interview with renowned scientist Prof Rossbach, the company has been hurtling from one milestone to the next!
 

	Share:	Vidac Pharma Holding PLC
	Country:	Israel / Great Britain
	Sector:	Biotechnology / Pharmaceuticals
	WKN:	A3DTUQ
	Current price:	1,53 EUR (Stuttgart, 14.08.2023)
	Target price:	3,50 EUR  on a 6 to 9 month horizon
	Our verdict:	STRONG BUY immediately and HOLD!

Vidac now announces a strategic partnership that should be quite something! The next clinical trial for advanced actinic keratosis will be conducted in close collaboration with Centroderm GmbH, led by Prof. Thomas Dirschka, a leading expert in the field of onco-dermatology. The two parties are working together to establish the exact protocol for the study, which will address advanced cases of actinic keratosis with a high proliferation profile that are most likely to develop into squamous cell carcinoma, a dangerous form of cancer.

Prof Dirschka's dermatology clinic has all the capacity to select and treat patients with potentially high risk and said, "We are delighted to be working with Vidac Pharma, which has developed a completely new approach to treating non-melanoma skin cancer, with potentially low side effects due to the specificity of its drug candidate."

Prof Herzberg, CEO of Vidac Pharma, commented, "Most lesions in actinic keratosis will not progress to squamous cell carcinoma. Our product targets those that do have this dangerous potential, and only those. In previous phase 2B trials, we have seen few side effects due to this specificity. We are very confident that this collaboration, combining the exceptional research capabilities of Centroderm and Prof Dirschka and our novel approach to reversing the Warburg effect, will help patients in the near future."

In our view, Vidac Pharma has absolute blockbuster potential and the development of this share is only just beginning and belongs in every speculative portfolio!

We would like to ask you to take a close look at the company, the people involved and, above all, the highly innovative approach to treating cancer. We are sure that you will also come to the conclusion that an investment here is absolutely worthwhile, because this is a share for long-term asset accumulation and not a short-term gamble!

About Vidac Pharma and a little history...

The German biochemist and physiologist Otto Warburg made groundbreaking discoveries about the metabolism of cancer cells back in 1923. He observed that after the cleavage (glycolysis) of sugar (glucose) to pyruvate, cancer cells excrete this as lactic acid for energy production (lactic acid fermentation) instead of burning it in the mitochondria like normal cells (citrate cycle). This behaviour is known as the Warburg effect or "aerobic glycolysis" and is still the basis for cancer diagnosis in positron emission tomography. His research was honoured with a Nobel Prize in Medicine in 1931.

Exactly 100 years later, Vidac Pharma from Israel has now succeeded in developing highly effective anti-cancer drugs based on the sugar metabolism of cancer cells discovered by Otto Warburg!

Vidac's technology restores normal cell metabolism, inducing apoptosis (programmed cell death) in malignant cells.

Cancer cells are characterised by a high rate of glycolysis (sugar metabolism) and suppressed apoptosis (programmed cell death), both of which promote proliferation and tumour formation. By specifically interfering with the HK2 stimulation of the cells, the drug succeeds in preventing the rapid spread (metastasis) of the tumour cells and in triggering the prevented apoptosis. At the same time, normal cells are not affected by Vidac's drugs!

Vidac's innovations target cancer cells that overexpress the metabolic control gene hexokinase 2 (HK2) to selectively kill them without harming surrounding healthy tissue. They directly interfere with the metabolism of the cancer cells and trigger previously suppressed programmed cell death (apoptosis), which returns the cells to normal metabolism, reducing immunodepression in the tumour environment while stimulating the anti-tumour immune response only in selected cancer cells.

The first lead compound, topical tuvatexib (VDA-1102), has demonstrated the highest safety and efficacy in patients with advanced actinic keratosis (AK/topical SCC), as shown in an FDA phase 2b clinical trial and an ongoing exploratory phase 2 trial in cutaneous T-cell lymphoma (CTCL):

"We are at an advanced preclinical stage, developing new, patented, highly potent molecules with the same mechanism of action for the treatment of solid tumours, either as monotherapy or in combination with immunotherapy and cell therapy, the effects of which are affected by hyperglycolysis of the tumour microenvironment," said Prof Max Herzberg, founder and CEO of Vidac.

Unlike existing drugs that cause severe side effects and pain, Vidac Pharma's VDA-1102 is the first drug in its class to treat NMSC (non-melanoma skin cancer) with minimal impact on surrounding healthy skin. Due to its unique properties and benefits, VDA-1102 is expected to become the drug of choice for first-line non-surgical therapy in a variety of NMSC indications.

The management team - nearly half a century of expertise in cancer research

Prof. Dr. Max Herzberg, founder and CEO of Vidac Pharma is a renowned scientist and entrepreneur and one of the founding fathers of the Israeli life sciences industry. Prof. Herzberg founded Orgenics and the EagerBio Group, is a co-founder of PixCell and has served as Chairman of several Israeli biotechnology companies and as Chairman of the European Molecular Biology Laboratory Enterprise Management (Heidelberg). Prof. Herzberg holds a PhD in molecular biology from the Weizmann Institute of Science.

Prof. Herzberg is supported by a high-calibre team of scientists, entrepreneurs and advisors. Board member Christian Policard is a former member of the Global Executive Committee and Executive Vice-President of Sanofi, one of the largest pharmaceutical companies in the world. Also on board is Yochai Richter, who guided Orbotech from its inception to its $4 billion exit and now supports Vidac Pharma on its way to becoming a successful global pharma player. For more information about the management team, the board of directors and the clinical advisors, please visit the company's website: https://vidacpharma.com/en/about-us/about-us


The pharmaceutical industry - a multi-billion dollar business

There are more than 200 million patients worldwide with non-melanoma skin cancer (NMSC) for whom there are currently inadequate treatment options. The market opportunity includes annual sales of more than $500 million for the first indication and annual sales of more than $2 billion for all indications of non-surgical tumour removal.

For CTCL, there is an unmet medical need of US $900 million worldwide, split evenly between the US, Europe and Asia-Pacific. CTCL is classified as a rare disease by the FDA, which requires an expedited approval process. Global trends such as the ageing population, global warming and increasing sun exposure in developed and emerging markets will contribute to further growth in the overall market accessible to Vidac Pharma in the coming years.

The solid tumour market is a multi-billion dollar market with products being developed for critical cancers such as pancreatic cancer, prostate cancer, lung cancer, etc.

Vidac Pharma, with its highly innovative approach, has an exceptionally strong patent portfolio with several patents already granted worldwide, covering the composition of the drugs as well as their application. Vidac Pharma is thus ideally positioned to become a global player in the pharmaceutical market!

Dear readers, in view of the importance of Vidac Pharma's drugs for the whole of humanity and the increasing global need for effective cancer drugs, we are convinced that Vidac Pharma is an absolute top investment with high multiplication potential.
We recommend building and HOLDING a strategic position!
Our verdict: STRONG BUY

About Vidac Pharma:
Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd Rehovot. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of first-in-class medicines to help people suffering from a range of oncology and dermatology diseases. www.vidacpharma.com

About Centroderm:
CentroDerm GmbH, under the direction of Prof. Thomas Dirschka and Dr. Lutz Schmitz, is a specialised treatment facility in the field of dermatology with - a dermatological private practice - a surgical treatment facility with a high-quality equipped dermatological operation area - a dermatological laser centre with twelve different state-of-the-art skin lasers - a dermatohistological laboratory - a molecular biology laboratory - a clinical study centre. www.centroderm.de

--------------------------------------------------------- Important information pursuant to Section 85 WpHG, Section 86 (1) WpHG, Article 20 MAR as well as the Delegated Regulation (EU) 2016/958 of the Commission of 09.03.2016 on the author of this publication and potential conflicts of interest: Details of the preparer of the financial analyses:

Mr. Achim Mehler, Analyst, as Editor-in-Chief, is responsible for the preparation of the texts and contents of this publication. This publication is published by Zantino GmbH, Peterstor 16, 36037 Fulda Germany, represented by its Managing Director Achim Mehler. Contact: info (at) zantino.de

The content of this publication is for information purposes only and does not constitute investment advice or any other recommendation within the meaning of the German Securities Trading Act (Wertpapierhandelsgesetz) by Zantino GmbH or any person or company associated with it. The content provided cannot replace investment advice. The contents of this publication are not to be understood as an assurance of any price developments and should not be understood as an invitation to enter into a transaction. The contents do not constitute an offer to sell or the solicitation of an offer to sell securities or rights or an invitation to trade in securities or rights. Accordingly, Zantino GmbH and its related persons or entities make no warranties or representations as to the accuracy, completeness or correctness of the information or opinions contained herein. We accept no liability for any direct or indirect damage caused by and/or in connection with the distribution and/or use of this publication. The statements correspond to the status at the time of the preparation of the publication. They may be outdated due to future developments without the publication being changed.

We point out that there is a conflict of interest and that we also own the recommended share and will buy and sell it at any time.

Important notes on the preparation of this financial analysis:

This financial analysis contains both facts and figures on the companies discussed as well as purely subjective value judgements, interpretations, estimates, projections, forecasts and price targets. We try to distinguish between these as transparently as possible in order to avoid misleading statements.

The main bases and benchmarks of our value judgements and valuations, of the shares discussed, are based on the following approach:

• Assessment and valuation of companies according to conventional valuation methods (basic valuation approach).
• Assessment of the potential of the company's future development (growth approach) and extrapolation to the corresponding valuation potential (price-potential analysis) as well as a possible company-share valuation based on potential profit expectations (P/E extrapolation).
• Assessment of the best-case scenario we expect in the absolute case of the company's success (blue sky potential approach)
• Effect of the strongly increased awareness of the recommended share expected by us on the share price due to an increase in demand on the market (especially decisive in the case of shares that are new to the market or recommended for the first time) as a result of publications (mostly buy recommendations) published by us or third parties (multiplier / momentum effect, hype), thus disproportionately increasing return/share price with a correspondingly increasing risk.
• Technical analysis of the share price according to common analysis methods, mostly to predict price signals (buy or sell signal, breakout of the share, determination of price targets, support or resistance areas, expected minimum movements or minimum counter-movements, prediction of signal points (if-then), etc.), largely based on expected mass psychology. (Technical approach)

Conventional valuation approaches are often difficult to apply meaningfully to young companies or companies that have not yet generated sales. Therefore, when valuing such companies, we tend to rely on the potential analysis we have calculated, as well as the assessment of the demand for such shares on the capital market. Ultimately, the market decides on the share price of a company. If there is excessive demand for a share as a result of extensive recommendations, it is possible that the share price will rise above average with a high trading volume. Although this leads to extreme profit opportunities, it correspondingly increases the risk of a bubble forming with a corresponding decline in the share price. The increased volatility of the share in such situations results in above-average profit and loss opportunities, both in both trading directions and in recurring counter-movements. Such market developments are also an important part of our trading recommendations and valuation approaches.

This publication deals exclusively with above-average volatile stocks.

Note on sources of information: We check the reliability of information sources in detail before using them and evaluate them subjectively according to their credibility and importance.

In doing so, we decide according to our own standards which sources we consider relevant, too conservative or too exaggerated. Finally, we make our recommendations on the basis of our personal assessments. When gathering information, we draw on numerous publicly available sources, such as press releases, ad hoc announcements, company news, publications and articles on the company discussed, common financial media in Germany and abroad, and also third-party company or industry analyses.

Only publicly available information and sources, as well as information disseminated by the company itself, are used in our publications.

Disclosure of conflicts of interest: The author of this publication and persons associated with him have significant holdings in the recommended shares. In addition, financial contributions are made to the publisher for the preparation of our recommendations. Payment is also made for the dissemination of this recommendation through numerous online media as well as other means of dissemination.

The publisher and persons associated with him expressly state that they plan to place buy and sell orders in the relevant share at any time the recommendation is made. Accordingly, the publisher is also highly interested in the success of the recommendation published by him.

Note on the handling of internal organisational duties: Despite existing conflicts of interest, our recommendations are made in the interest of the recipients. This recommendation is independent to the extent that the publisher is firmly convinced that the published price targets are most likely to be achieved and that the recipient can achieve above-average returns with the recommended share. Due to the small size of the publisher, internal control of the compliance processes of the employees and other parties involved in this publication is manageable.

The following authority is responsible for the author of this publication:

Federal Financial Supervisory Authority (BaFin)
Marie-Curie-Str. 24-28
D-60439 Frankfurt (Germany)
By accepting this publication, you accept the above restrictions as binding on you. Additional information on the contents of this publication is available upon request.